NI Xiaojia, HU Haitang, ZHANG Ming, HU Jinqing, SHANG Dewei, WEN Yuguan. Pharmacokinetics of blonanserin tablets in Chinese healthy volunteers[J]. Journal of China Pharmaceutical University, 2013, 44(6): 540-542. DOI: 10.11665/j.issn.1000-5048.20130610
Citation:
NI Xiaojia, HU Haitang, ZHANG Ming, HU Jinqing, SHANG Dewei, WEN Yuguan. Pharmacokinetics of blonanserin tablets in Chinese healthy volunteers[J]. Journal of China Pharmaceutical University, 2013, 44(6): 540-542. DOI: 10.11665/j.issn.1000-5048.20130610
NI Xiaojia, HU Haitang, ZHANG Ming, HU Jinqing, SHANG Dewei, WEN Yuguan. Pharmacokinetics of blonanserin tablets in Chinese healthy volunteers[J]. Journal of China Pharmaceutical University, 2013, 44(6): 540-542. DOI: 10.11665/j.issn.1000-5048.20130610
Citation:
NI Xiaojia, HU Haitang, ZHANG Ming, HU Jinqing, SHANG Dewei, WEN Yuguan. Pharmacokinetics of blonanserin tablets in Chinese healthy volunteers[J]. Journal of China Pharmaceutical University, 2013, 44(6): 540-542. DOI: 10.11665/j.issn.1000-5048.20130610
To study the pharmacokinetics of blonanserin tablets in thirty Chinese healthy volunteers grouped into three single-dose levels of 4, 8 and 12 mg. The blood samples were collected up to 60 h after oral administration. The plasma concentration of blonanserin was determined by a validated LC-MS/MS method. The pharmacokinetic parameters were calculated by DAS 3. 2. 4 software. The main pharmacokinetic parameters of blonanserin after the single dose of 4, 8 and 12 mg were as follows: cmax were(539. 61±388. 74), (1 190. 39±736. 51)and(1 637. 34±481. 45)ng/L; tmax were(1. 00±0. 47), (1. 38 ±0. 79)and(1. 43±0. 94)h; t1/2 were(12. 05±3. 49), (14. 76±3. 78)and(13. 68±3. 92)h; AUC0-60 h were(4 692. 21±3 041. 75), (7 964. 42±3 988. 07)and(9 648. 22±2 565. 07)ng ·h/L; AUC0-∞ were(5 060. 91±3 146. 10), (8 547. 61±4 209. 87)and(9 986. 15±2 659. 51)ng ·h/L, respectively. The main pharmacokinetic parameters of blonanserin positively correlated with the dose over the range of 4-12 mg.
Chang MH,Li YH.A new antipsychotic agent:blonanserin[J].Chin J New Drugs Clin Rem(中国新药与临床杂志),2010(29):571-575.
[2]
Wen YG,Ni XJ,Zhang M,et al.Simultaneous determination of blonanserin and its metabolite in human plasma and urine by liquid chromatography-tandem mass spectrometry:application to a pharmacokinetic study[J].J Chromatogr B Analyt Technol Biomed Life Sci,2012,903(15):46-52.
[3]
Suzuki H,Gen K.The relationship between the plasma concentration of blonanserin,and its plasma anti-serotonin 5-HT(2A)activity/anti-dopamine D2 activity ratio and drug-induced extrapyramidal symptoms[J].Psychiatry Clin Neurosci,2012,66(2):146-152.
[4]
Saruwatari J,Yasui-Furukori N,Inoue Y,et al.Effect of dose timing in relation to food intake on systemic exposure to blonanserin[J].Eur J Clin Pharmacol,2010,66(9):899-902.